Substance / Medication

Fludarabine phosphate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
Lichtman Stuart M, Etcubanas Erlinda, Budman Daniel R et al. · Cancer Invest · 2002
PMID: 12449721Observational
Design of an innovative aptasensor for the detection of chemotherapeutic drug Fludarabine phosphate.
Alanazi Shamsa, Rhouati Amina, Chrouda Amani et al. · Sci Rep · 2024
PMID: 39487287OtherFull text (PMC)
Using Gold Nanoparticles as Delivery Vehicles for Targeted Delivery of Chemotherapy Drug Fludarabine Phosphate to Treat Hematological Cancers.
Song Steven, Hao Yuzhi, Yang Xiaoyan et al. · J Nanosci Nanotechnol · 2016
PMID: 27455673Other
Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
Yin Wei, Karyagina Elena V, Lundberg Ante S et al. · Biopharm Drug Dispos · 2010
PMID: 19862681Other
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
Walker S, Palmer S, Erhorn S et al. · Health Technol Assess · 2009
PMID: 19567212Other
In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.
Sorscher Eric J, Hong Jeong S, Allan Paula W et al. · Cancer Chemother Pharmacol · 2012
PMID: 22760227PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fludarabine phosphate (substance)
SNOMED CT
108765002
UMLS CUI
C0060483

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.